Exciting news.
I can't wait to see the look on Jon's face at 10:30am.
Jon has mentioned that 2591 is expected to be like but better than Trofinetide with less side effects. Well, we are hearing news about Daybue that its benefits for the person with Rhett continue to improve as they continue to take Daybue over time. So I am wondering that someone with PMS may obtain similar improving benefits from 2591 over time. So could the others areas that were not considered significant in the Phase 2 trial hopefully may come to life and improve the longer the person takes 2591? It would be good to hear Jon's view in this.
Enjoy today all.
Yahoo
- Forums
- ASX - By Stock
- NEU
- Ann: P2 trial shows significant improvements in Phelan-McDermid
Ann: P2 trial shows significant improvements in Phelan-McDermid, page-50
-
- There are more pages in this discussion • 161 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.14 |
Change
0.010(0.08%) |
Mkt cap ! $1.683B |
Open | High | Low | Value | Volume |
$13.22 | $13.32 | $13.01 | $1.178M | 89.69K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 357 | $13.14 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.15 | 17 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 7 | 13.050 |
4 | 534 | 13.040 |
6 | 2287 | 13.030 |
4 | 2758 | 13.020 |
10 | 3504 | 13.010 |
Price($) | Vol. | No. |
---|---|---|
13.070 | 537 | 9 |
13.080 | 960 | 9 |
13.090 | 713 | 5 |
13.100 | 640 | 5 |
13.110 | 722 | 4 |
Last trade - 11.28am 21/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online